Says had “multiple”sessions with the board and with the world’s foremost scientific medical, regulatory and legal experts. Comments taken from Kimberly-Clark’s (KMB) conference call discussing its proposed acquisition of Kenvue (KVUE).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KMB:
- M&A: Diaper Group Kimberly-Clark Leaks 15% After $48.7B Purchase of Tylenol Maker Kenvue
- Kimberly-Clark Announces Merger Agreement with Kenvue
- Kimberly-Clark price target raised to $132 from $131 at Barclays
- Kimberly-Clark to acquire Kenvue for $21.01 per share in cash, stock
- Kimberly-Clark to acquire Kenvue at enterprise value of $48.7B